Harvard Bioscience (HBIO) 2.79 $HBIO Harvard Bi
Post# of 273319
Posted On: 09/02/2016 11:16:26 PM
Harvard Bioscience (HBIO) 2.79 $HBIO
Harvard Bioscience (HBIO): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:46AM CDT
Harvard Bioscience Inc. (HBIO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
HBIO: 2.79 (+0.09)
Harvard Bioscience Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Jul 28, 5:15AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial results for the three and six months ended June 30, 2016.
HBIO: 2.79 (+0.09)
Harvard Bioscience to Attend The Benchmark Company, LLC One-on-One Conference in Milwaukee, Wisconsin on June 2, 2016
GlobeNewswire - Tue May 31, 5:30AM CDT
Harvard Bioscience, Inc. (NASDAQ:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will participate in The Benchmark Company, LLC One-on-One Conference at The Pfister Hotel in Milwaukee, Wisconsin on Thursday, June 2, 2016.
HBIO: 2.79 (+0.09)
Harvard Bioscience reports 1Q loss
Automated Insights - Thu May 12, 5:15AM CDT
HOLLISTON, Mass. (AP) _ Harvard Bioscience Inc. (HBIO) on Thursday reported a loss of $636,000 in its first quarter.
HBIO: 2.79 (+0.09)
Harvard Bioscience Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 12, 5:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"
, a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported its financial results for the three months ended March 31, 2016.
HBIO: 2.79 (+0.09)
Harvard Bioscience Regains Compliance with NASDAQ's Continued Listing Requirements
GlobeNewswire - Wed May 04, 3:16PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company" , a global developer, manufacturer and marketer of a broad range of solutions to advance life science, announced today that it received written notification from NASDAQ (the "Notice" stating the Company has regained compliance with NASDAQ's Listing Rule 5250(c)(1) and the matter is now closed.
HBIO: 2.79 (+0.09)
Harvard Bioscience Reports Fourth Quarter and Year-End 2015 Results, Preliminary First Quarter 2016 Revenues and 2016 Financial Guidance
GlobeNewswire - Fri Apr 29, 3:45PM CDT
Reports Results of Embezzlement Investigation
HBIO: 2.79 (+0.09)
Harvard Bioscience Delays Filing of Annual Report on Form 10-K and Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2015 Revenue
GlobeNewswire - Mon Mar 28, 3:15PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company" , a global developer, manufacturer and marketer of a broad range of solutions to advance life science, today announced that the filing of its Annual Report on Form 10-K for the year ended December 31, 2015 (the "Form 10-K" would not occur prior to the extended March 30, 2016 deadline, and also announced preliminary unaudited revenue for the three and twelve months ended December 31, 2015.
HBIO: 2.79 (+0.09)
Investors Flock to Pressure BioSciences as Its Patented PCT Platform Goes Mainstream
ACCESSWIRE - Fri Jan 15, 8:35AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 15, 2016 / Pressure BioSciences Inc. (OTCQB: PBIO) just announced that it exceeded its $5 million fundraising goal and approved the opening of an additional $1.25 million over-subscription amount in its PIPE offering. With growing revenue, a new multi-national partner (see below), and a potential up-listing in the near future, accredited investors have been flocking into the company's stock through the private offering, and retail investors have been flocking into the company's stock in the open market. Both of these may be bullish signs for individual investors for the coming year.
HBIO: 2.79 (+0.09), TMO: 151.18 (+0.23), HTGM: 2.71 (+0.06), DHR: 81.19 (-0.25), WAT: 156.19 (+0.09)
BUYINS.NET: RAIL, APU, HBIO, MMP, AMKR, STLD Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Dec 18, 6:40AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Freightcar America Inc (NASDAQ:RAIL), Amerigas Partners LP (NYSE:APU), Harvard Bioscience Inc (NASDAQ:HBIO), Magellan Midstream Partners LP (NYSE:MMP), Amkor Technology Inc (NASDAQ:AMKR), Steel Dynamics Inc (NASDAQ:STLD) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
STLD: 24.32 (-0.39), AMKR: 9.25 (+0.01), HBIO: 2.79 (+0.09), APU: 46.07 (+0.67), RAIL: 14.23 (+0.12), MMP: 70.81 (+0.28)
Pressure BioSciences Cleans Up Balance Sheet with Successful PIPE Financing
ACCESSWIRE - Wed Dec 16, 8:20AM CST
Improved Balance Sheet Paves Way for Increased Revenue, Potential Uplisting and Stronger Shareholder Value
HBIO: 2.79 (+0.09), NSTG: 16.45 (+0.20)
Falling Earnings Estimates Signal Weakness Ahead for Harvard Bioscience (HBIO)
Zacks Equity Research - Zacks Investment Research - Wed Nov 25, 7:31AM CST
It may not be a good decision to keep Harvard Bioscience (HBIO) stock in your portfolio anymore.
HBIO: 2.79 (+0.09), BRKR: 22.38 (-0.06)
Strong Revenue Growth in the $6 Billion Biological Sample Preparation Market
ACCESSWIRE - Fri Nov 13, 8:20AM CST
REDONDO BEACH, CA / ACCESSWIRE / November 13, 2015 / Biological sample preparation may sound like a commoditized industry, but the $6 billion market serving 500,000 scientists across 80,000 research labs is ripe for innovation. With traditional technologies like blenders or freeze-thaw cycles employing mechanical disruption, current sample preparation methods are a bottleneck for researchers in terms of the number of samples that can be prepared at any given time and the reproducibility of the results generated by these processes.
HBIO: 2.79 (+0.09), NSTG: 16.45 (+0.20)
Harvard Bioscience Reports Third Quarter 2015 Financial Results and Updates Outlook for Full-Year 2015
GlobeNewswire - Thu Oct 29, 5:30AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial results for the three and nine months ended September 30, 2015.
HBIO: 2.79 (+0.09)
Harvard Bioscience to Showcase Array of New Products at Society for Neuroscience 2015 Annual Meeting in Chicago on October 18-21
GlobeNewswire - Fri Oct 16, 9:00AM CDT
Harvard Bioscience, Inc. (NASDAQ:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will feature new and existing products from its expanded portfolio of brands at the Society for Neuroscience 2015 Annual Meeting at Chicago's McCormick Place Convention Center on October 18-21. This year, for the first time, the Company's Harvard Apparatus booth will incorporate a host of instruments from Harvard Bioscience's three recently acquired companies--HEKA Elektronik, Multi Channel Systems and Triangle BioSystems International--directly alongside those from its established brands. There will also be two dedicated workstations in the Harvard Apparatus booth for scheduled one-on-one product demonstrations and training sessions.
HBIO: 2.79 (+0.09)
Harvard Bioscience Schedules Third Quarter 2015 Conference Call for October 29 at 8:30 AM ET
GlobeNewswire - Thu Oct 15, 3:05PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its third quarter 2015 before market trading hours on Thursday, October 29, 2015. A conference call to discuss the company's third quarter 2015 financial results and its operations is scheduled for that same date at 8:30 AM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
HBIO: 2.79 (+0.09)
BUYINS.NET: HBIO SqueezeTrigger Price is $4.53. There is $6,266,352 That Short Sellers Still Need To Cover.
M2 - Fri Sep 11, 12:06PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Harvard Bioscience Inc (NASDAQ:HBIO) in real time and just received an alert that HBIO is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 1374200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $4.53. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
HBIO: 2.79 (+0.09)
Harvard Bioscience posts 2Q profit
Automated Insights - Thu Jul 30, 5:42AM CDT
HOLLISTON, Mass. (AP) _ Harvard Bioscience Inc. (HBIO) on Thursday reported second-quarter net income of $349,000.
HBIO: 2.79 (+0.09)
Harvard Bioscience (HBIO): Moving Average Crossover Alert
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:46AM CDT
Harvard Bioscience Inc. (HBIO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
HBIO: 2.79 (+0.09)
Harvard Bioscience Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Jul 28, 5:15AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial results for the three and six months ended June 30, 2016.
HBIO: 2.79 (+0.09)
Harvard Bioscience to Attend The Benchmark Company, LLC One-on-One Conference in Milwaukee, Wisconsin on June 2, 2016
GlobeNewswire - Tue May 31, 5:30AM CDT
Harvard Bioscience, Inc. (NASDAQ:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will participate in The Benchmark Company, LLC One-on-One Conference at The Pfister Hotel in Milwaukee, Wisconsin on Thursday, June 2, 2016.
HBIO: 2.79 (+0.09)
Harvard Bioscience reports 1Q loss
Automated Insights - Thu May 12, 5:15AM CDT
HOLLISTON, Mass. (AP) _ Harvard Bioscience Inc. (HBIO) on Thursday reported a loss of $636,000 in its first quarter.
HBIO: 2.79 (+0.09)
Harvard Bioscience Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 12, 5:00AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"
, a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported its financial results for the three months ended March 31, 2016. HBIO: 2.79 (+0.09)
Harvard Bioscience Regains Compliance with NASDAQ's Continued Listing Requirements
GlobeNewswire - Wed May 04, 3:16PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"
, a global developer, manufacturer and marketer of a broad range of solutions to advance life science, announced today that it received written notification from NASDAQ (the "Notice" stating the Company has regained compliance with NASDAQ's Listing Rule 5250(c)(1) and the matter is now closed. HBIO: 2.79 (+0.09)
Harvard Bioscience Reports Fourth Quarter and Year-End 2015 Results, Preliminary First Quarter 2016 Revenues and 2016 Financial Guidance
GlobeNewswire - Fri Apr 29, 3:45PM CDT
Reports Results of Embezzlement Investigation
HBIO: 2.79 (+0.09)
Harvard Bioscience Delays Filing of Annual Report on Form 10-K and Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2015 Revenue
GlobeNewswire - Mon Mar 28, 3:15PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO) (the "Company"
, a global developer, manufacturer and marketer of a broad range of solutions to advance life science, today announced that the filing of its Annual Report on Form 10-K for the year ended December 31, 2015 (the "Form 10-K" would not occur prior to the extended March 30, 2016 deadline, and also announced preliminary unaudited revenue for the three and twelve months ended December 31, 2015. HBIO: 2.79 (+0.09)
Investors Flock to Pressure BioSciences as Its Patented PCT Platform Goes Mainstream
ACCESSWIRE - Fri Jan 15, 8:35AM CST
REDONDO BEACH, CA / ACCESSWIRE / January 15, 2016 / Pressure BioSciences Inc. (OTCQB: PBIO) just announced that it exceeded its $5 million fundraising goal and approved the opening of an additional $1.25 million over-subscription amount in its PIPE offering. With growing revenue, a new multi-national partner (see below), and a potential up-listing in the near future, accredited investors have been flocking into the company's stock through the private offering, and retail investors have been flocking into the company's stock in the open market. Both of these may be bullish signs for individual investors for the coming year.
HBIO: 2.79 (+0.09), TMO: 151.18 (+0.23), HTGM: 2.71 (+0.06), DHR: 81.19 (-0.25), WAT: 156.19 (+0.09)
BUYINS.NET: RAIL, APU, HBIO, MMP, AMKR, STLD Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Dec 18, 6:40AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Freightcar America Inc (NASDAQ:RAIL), Amerigas Partners LP (NYSE:APU), Harvard Bioscience Inc (NASDAQ:HBIO), Magellan Midstream Partners LP (NYSE:MMP), Amkor Technology Inc (NASDAQ:AMKR), Steel Dynamics Inc (NASDAQ:STLD) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
STLD: 24.32 (-0.39), AMKR: 9.25 (+0.01), HBIO: 2.79 (+0.09), APU: 46.07 (+0.67), RAIL: 14.23 (+0.12), MMP: 70.81 (+0.28)
Pressure BioSciences Cleans Up Balance Sheet with Successful PIPE Financing
ACCESSWIRE - Wed Dec 16, 8:20AM CST
Improved Balance Sheet Paves Way for Increased Revenue, Potential Uplisting and Stronger Shareholder Value
HBIO: 2.79 (+0.09), NSTG: 16.45 (+0.20)
Falling Earnings Estimates Signal Weakness Ahead for Harvard Bioscience (HBIO)
Zacks Equity Research - Zacks Investment Research - Wed Nov 25, 7:31AM CST
It may not be a good decision to keep Harvard Bioscience (HBIO) stock in your portfolio anymore.
HBIO: 2.79 (+0.09), BRKR: 22.38 (-0.06)
Strong Revenue Growth in the $6 Billion Biological Sample Preparation Market
ACCESSWIRE - Fri Nov 13, 8:20AM CST
REDONDO BEACH, CA / ACCESSWIRE / November 13, 2015 / Biological sample preparation may sound like a commoditized industry, but the $6 billion market serving 500,000 scientists across 80,000 research labs is ripe for innovation. With traditional technologies like blenders or freeze-thaw cycles employing mechanical disruption, current sample preparation methods are a bottleneck for researchers in terms of the number of samples that can be prepared at any given time and the reproducibility of the results generated by these processes.
HBIO: 2.79 (+0.09), NSTG: 16.45 (+0.20)
Harvard Bioscience Reports Third Quarter 2015 Financial Results and Updates Outlook for Full-Year 2015
GlobeNewswire - Thu Oct 29, 5:30AM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial results for the three and nine months ended September 30, 2015.
HBIO: 2.79 (+0.09)
Harvard Bioscience to Showcase Array of New Products at Society for Neuroscience 2015 Annual Meeting in Chicago on October 18-21
GlobeNewswire - Fri Oct 16, 9:00AM CDT
Harvard Bioscience, Inc. (NASDAQ:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will feature new and existing products from its expanded portfolio of brands at the Society for Neuroscience 2015 Annual Meeting at Chicago's McCormick Place Convention Center on October 18-21. This year, for the first time, the Company's Harvard Apparatus booth will incorporate a host of instruments from Harvard Bioscience's three recently acquired companies--HEKA Elektronik, Multi Channel Systems and Triangle BioSystems International--directly alongside those from its established brands. There will also be two dedicated workstations in the Harvard Apparatus booth for scheduled one-on-one product demonstrations and training sessions.
HBIO: 2.79 (+0.09)
Harvard Bioscience Schedules Third Quarter 2015 Conference Call for October 29 at 8:30 AM ET
GlobeNewswire - Thu Oct 15, 3:05PM CDT
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its third quarter 2015 before market trading hours on Thursday, October 29, 2015. A conference call to discuss the company's third quarter 2015 financial results and its operations is scheduled for that same date at 8:30 AM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
HBIO: 2.79 (+0.09)
BUYINS.NET: HBIO SqueezeTrigger Price is $4.53. There is $6,266,352 That Short Sellers Still Need To Cover.
M2 - Fri Sep 11, 12:06PM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring Harvard Bioscience Inc (NASDAQ:HBIO) in real time and just received an alert that HBIO is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 1374200 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $4.53. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
HBIO: 2.79 (+0.09)
Harvard Bioscience posts 2Q profit
Automated Insights - Thu Jul 30, 5:42AM CDT
HOLLISTON, Mass. (AP) _ Harvard Bioscience Inc. (HBIO) on Thursday reported second-quarter net income of $349,000.
HBIO: 2.79 (+0.09)
(0)
(0)